Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 4/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239316 | 1.00 | LPAR5 (0.38) | LPAR5CYP17A1CHRNA7OPRM1OPRK1 | |
| SCHEMBL2862947 | 0.87 | LPAR5 (0.35) | LPAR5CYP17A1CHRNA7OPRM1OPRK1 | |
| SCHEMBL2862942 | 0.87 | LPAR5 (0.35) | LPAR5CYP17A1CHRNA7OPRM1OPRK1 | |
| SCHEMBL2839122 | 0.86 | LPAR5 (0.47) | LPAR5CYP17A1CHRNA7OPRM1OPRK1 | |
| SCHEMBL2839118 | 0.86 | LPAR5 (0.47) | LPAR5CYP17A1CHRNA7OPRM1OPRK1 | |
| SCHEMBL2869459 | 0.86 | CYP17A1 (0.35) | LPAR5CYP17A1NPC1RAB9AATM | |
| SCHEMBL2869461 | 0.86 | CYP17A1 (0.35) | LPAR5CYP17A1NPC1RAB9AATM | |
| SCHEMBL2867990 | 0.85 | RAB9A (0.36) | NPC1RAB9ADPP4DPP7 | |
| SCHEMBL2867987 | 0.85 | RAB9A (0.36) | NPC1RAB9ADPP4DPP7 | |
| SCHEMBL4235120 | 0.84 | NOTUM (0.37) | NPC1RAB9ADPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | claimed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | claimed |
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | LPAR5 905/4885CYP17A1 4881/4885CHRNA7 13/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | LPAR5 131/4885CYP17A1 2390/4885CHRNA7 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.